Loading...
•
Dec 31, 2022
Harmony Biosciences Q4 2022 Earnings Report
Harmony Biosciences' Q4 2022 financial performance was reported, featuring revenue growth and advancements in clinical development programs.
Key Takeaways
Harmony Biosciences reported a strong Q4 2022, with net product revenues reaching $128.3 million, a 40.7% increase compared to the same period in 2021. GAAP net income for the quarter was $48.5 million, or $0.79 per diluted share, while non-GAAP adjusted net income was $61.9 million, or $1.01 per diluted share.
Net product revenues for Q4 2022 were $128.3 million, up from $91.2 million in the same period in 2021.
GAAP net income for Q4 2022 was $48.5 million, or $0.79 per diluted share, compared to $22.7 million, or $0.38 per diluted share, for the same period in 2021.
Non-GAAP adjusted net income for Q4 2022 was $61.9 million, or $1.01 per diluted share, compared to $30.4 million, or $0.50 per diluted share, for the same period in 2021.
The average number of patients on WAKIX increased to approximately 4,900 for the quarter ended December 31, 2022.
Revenue by Segment
Forward Guidance
Harmony remains confident in the ongoing performance of WAKIX and focuses on advancing life cycle management programs for pitolisant and acquiring new assets to build out the pipeline to drive additional growth.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...